MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 05.03.2026
NextCure EV/EBITDA 2011-2026 | NXTC
EV/EBITDA Jährlich NextCure
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.03 | -7.67 | -18.8 | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -2.03 | -18.8 | -9.49 |
EV/EBITDA anderer Aktien in der Pharmaeinzelhändler
| Name | EV/EBITDA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
9.24 | $ 3.46 | 1.72 % | $ 1.03 B |  Canada |
 |
Altimmune
ALT
|
-1.66 | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
10.7 | $ 350.07 | 0.63 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.3 | $ 19.49 | -0.05 % | $ 911 M | USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-15.7 | $ 220.18 | -0.77 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Aurinia Pharmaceuticals
AUPH
|
-7.69 | $ 14.83 | 5.78 % | $ 1.99 B | Canada |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.38 | $ 1.42 | 3.64 % | $ 362 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
Axsome Therapeutics
AXSM
|
-8.03 | $ 154.69 | -1.42 % | $ 7.7 B | USA |
 |
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
671 | $ 54.66 | 0.97 % | $ 10.5 B | USA |
 |
Benitec Biopharma
BNTC
|
0.734 | $ 11.25 | 2.46 % | $ 463 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-8.81 | $ 12.74 | - | $ 768 M | USA |
 |
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Coherus BioSciences
CHRS
|
-4.11 | $ 1.59 | 4.28 % | $ 186 M | USA |
 |
Calithera Biosciences
CALA
|
-7.96 | - | -10.95 % | $ 876 K | USA |
 |
Cellectis S.A.
CLLS
|
-1.37 | $ 3.38 | 1.05 % | $ 116 M | France |
 |
Cara Therapeutics
CARA
|
-6.7 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
0.0235 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-0.833 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-3.86 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
-7.07 | $ 2.13 | 1.9 % | $ 199 M | Israel |
 |
Denali Therapeutics
DNLI
|
-14.1 | $ 20.96 | 3.89 % | $ 3.45 B | USA |
 |
Dyadic International
DYAI
|
-6.69 | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
-3.52 | $ 6.33 | 1.28 % | $ 456 K | USA |